Tag Archive for: multiple myeloma

Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma

/in

Recognizes the potential of HDP-101 to address a serious or life-threatening condition with high unmet medical needs Enables more frequent engagement with FDA and eligibility for rolling review to support expedited development and review Ladenburg, Germany, 23 October 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), […]

Read more

Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business

/in

Clinical trial with ATAC candidate HDP-101 in multiple myeloma shows promising data Cohort 7 of the Phase I dose escalation study with HDP-101 safe and well tolerated; Cohort 8 started First patient in clinical study dosed with the second ATAC candidate HDP-102 in the non-Hodgkin lymphoma (NHL) indication Amendment of contract with HealthCare Royalty; payment of […]

Read more

Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025

/in

HDP-101 demonstrated complete response in one female patient from cohort 5 R&D Webinar to be hosted on 17 June 2025 Ladenburg, Germany, 14 May 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it will be presenting new clinical data on its lead Amanitin-based […]

Read more

Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025

/in

Cohort 7 of the clinical trial of HDP-101 in multiple myeloma safe and well tolerated Cohort 8 expected to start soon Clinical development of the second ADC program HDP-102 in patients with non-Hodgkin lymphoma (NHL) has started Amendment of contract with HealthCare Royalty; payment of USD 20 million significantly extends cash reach Ladenburg, Germany, 24 […]

Read more

Interim Management Statement on the First Three Months of 2024

/in

First efficacy data from the clinical trial with HDP-101 in multiple myeloma Professor Andreas Pahl becomes Chief Executive Officer Successful financing activities Sale of a portion of future royalties for Zircaix™ to HealthCare Royalty finances further development of the ADC pipeline Ladenburg, Germany, 25 April 2024 – Heidelberg Pharma AG (FSE: HPHA) today reported on the […]

Read more